Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria

February 8, 2020 updated by: Wu Jiang

Beijing Center for Disease Prevention and Control

Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.

Study Overview

Status

Completed

Conditions

Detailed Description

Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.

Study Type

Observational

Enrollment (Actual)

76220

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Beijing, China
        • Changping District Center for Disease Prevention and Control
      • Beijing, China
        • FangShan District Center for Disease Prevention and Control
      • Beijing, China
        • Haidian District Center for Disease Prevention and Control
      • Beijing, China
        • Miyun District Center for Disease Prevention and Control
      • Beijing, China
        • Tongzhou District Center for Disease Prevention and Control
    • Beijing
      • Beijing, Beijing, China
        • Chaoyang District Center for Disease Control and Prevention
      • Beijing, Beijing, China, 101400
        • Huairou District Center for Disease Prevention and Control
      • Beijing, Beijing, China, 102600
        • Daxing District Center for Disease Prevention and Control
      • Beijing, Beijing, China, 100120
        • Xicheng District Center for Disease Prevention and Control
      • Beijing, Beijing, China
        • Dongcheng District Center for Disease Control and Prevention
      • Beijing, Beijing, China
        • Fengtai District Center for Disease Control and Prevention

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The study population are Residents with medical insurance who were older than 25 years and lived in Beijing more than 6 months. The population who are with pacemakers and ascites, pregnant, and whose wound was not cured at right upper abdomen were excluded.

Description

Inclusion Criteria:

  • older than 25 years old;
  • Residents with medical insurance coverage lived in Beijing more than 6 months .

Exclusion Criteria:

  • Persons with pacemakers;
  • Pregnant women;
  • Persons with ascites;
  • The one whose wound was not cured at the right upper abdomen

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HBsAg positive rate
Time Frame: Baseline
Complete HBsAg tests for more than 60,000 people over the age of 25 in Beijing
Baseline
Average rate of chronic hepatitis B accepting antiviral treatment
Time Frame: Baseline
The one who is eligible for HBV treated criteria based on community in 25 and over years old in Beijing.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wu Jiang

Investigators

  • Study Director: Jiang Wu, Beijing Center for Disease Prevention and Control

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 28, 2017

Primary Completion (Actual)

September 28, 2019

Study Completion (Actual)

January 10, 2020

Study Registration Dates

First Submitted

February 4, 2020

First Submitted That Met QC Criteria

February 8, 2020

First Posted (Actual)

February 11, 2020

Study Record Updates

Last Update Posted (Actual)

February 11, 2020

Last Update Submitted That Met QC Criteria

February 8, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BJCDCWJ202001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis B

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe